Ardent Health Partners, Inc. (ARDT) AI Stock Analysis

• Market Cap: $1.92B
• Dividend Yield: N/A
• Average Volume (3M): 273.19K
• Price to Earnings (P/E): 8.5
• Beta (1Y): 0.39
• Revenue Growth: 8.91%
• EPS Growth: 193.92%
• Country: US
• Employees: 19,200
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Care Facilities
• EPS (TTM): 0.29
• Shares Outstanding: 143,043,660
• 10 Day Avg. Volume: 339,743
• 30 Day Avg. Volume: 273,187
• PEG Ratio: 0.55
• Price to Book (P/B): 3.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.14
• Enterprise Value/Market Cap: 2.21
• Enterprise Value/Revenue: 0.19
• Enterprise Value/Gross Profit: 1.05
• Enterprise Value/Ebitda: 2.32
• 1Y Price Target: $21.17
• Price Target Upside: 57.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 72 Outperform
• Price Target: $15.00 ▲(11.77%Upside)

Ardent Health Partners, Inc. shows strong financial performance, with improvements in profitability and cash flow. The earnings call provided positive insights, indicating effective growth strategies and operational improvements. However, mixed technical indicators and the absence of a dividend yield moderate the overall score. The company's valuation suggests potential for appreciation, supported by a low P/E ratio.

Positive Factors

Financial Outlook

2025-26 estimates and price target remain unchanged, indicating confidence in the company's financial outlook.

Growth Strategy

Management is working on entry into new markets through joint ventures and mergers and acquisitions.

Investment Potential

The company's investment case remains strong with good sector trends and a belief that the company is materially under-earning its potential with its outpatient network strategy.

Negative Factors

Government Spending

The potential risk of meaningful government spending cuts has resurfaced and is weighing on the stock.

Medicaid Coverage

Work requirements for Medicaid beneficiaries are expected to reduce some Medicaid coverage and divert a portion of the lost coverage to commercial payors.

Regulatory Risk

There is uncertainty about the timing of CMS approval, which has led to the shift of the anticipated $65 million DPP contribution from NM from 2Q to 3Q.

Ardent Health Partners, Inc. Business Overview & Revenue Model

Company Description

Ardent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, LLC is a subsidiary of EGI-AM Investments, L.L.C.

How the Company Makes Money

null

Ardent Health Partners, Inc. Financial Statement Overview

Summary

Ardent Health Partners, Inc. exhibits a strong financial position with significant improvements in profitability, cash flow, and financial stability. The company's strategic focus on cost management and operational efficiency has led to enhanced margins and cash generation. Despite the positive trajectory, achieving higher returns on equity would further strengthen its financial performance. Overall, Ardent Health Partners is well-positioned for future growth and financial resilience.

Income Statement

Ardent Health Partners, Inc. shows a strong income statement with a consistent revenue growth at an annual rate of 10.3% from 2023 to 2024. The gross profit margin is high at 57.5%, indicating effective cost management. The company's net profit margin increased significantly from 0.9% in 2023 to 3.5% in 2024, demonstrating improved profitability. The EBIT and EBITDA margins also improved, reflecting enhanced operational efficiency.

Balance Sheet

The balance sheet reflects a solid equity base, with stockholders' equity increasing from $670.9 million in 2023 to $1.52 billion in 2024. The debt-to-equity ratio has significantly decreased from 3.57 in 2023 to 0.76 in 2024, indicating reduced financial leverage and risk. The equity ratio improved to 30.7%, highlighting stronger financial stability. However, the return on equity is relatively modest at 13.8%, suggesting room for improved returns on shareholder investments.

Cash Flow

The cash flow statement is robust, with a notable free cash flow growth of 51.3% from 2023 to 2024, indicating better cash management. The operating cash flow to net income ratio is healthy at 1.50, showing strong cash generation against accounting profits. The free cash flow to net income ratio is at 0.61, reflecting efficient cash flow utilization. Overall, the company demonstrates strong cash flow generation, supporting its operations and investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2018	Dec 2017
Income Statement
Total Revenue	6.02B	5.97B	5.41B	5.13B	4.16B	3.00B
Gross Profit	4.03B	3.43B	4.42B	4.17B	4.16B	3.00B
EBITDA	567.09M	555.92M	350.00M	531.70M	281.84M	230.91M
Net Income	224.68M	210.34M	50.29M	188.91M	-143.02M	-35.65M
Balance Sheet
Total Assets	4.91B	4.96B	4.73B	4.86B	2.75B	2.37B
Cash, Cash Equivalents and Short-Term Investments	495.04M	556.78M	437.58M	456.12M	59.66M	71.96M
Total Debt	1.19B	2.28B	2.40B	2.39B	1.26B	952.69M
Total Liabilities	3.35B	3.43B	3.65B	3.81B	2.03B	1.61B
Stockholders Equity	1.56B	1.52B	670.90M	639.05M	331.64M	377.72M
Cash Flow
Free Cash Flow	115.91M	127.52M	84.29M	-189.47M	-1.07M	-2.06M
Operating Cash Flow	302.48M	315.03M	221.70M	-38.36M	159.59M	119.47M
Investing Cash Flow	-211.94M	-220.46M	-137.98M	46.58M	-525.11M	-983.27M
Financing Cash Flow	31.74M	24.64M	-102.26M	-270.33M	353.22M	843.15M

Ardent Health Partners, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Negative. The current price of 13.42 is below the 20-day moving average (MA) of 13.50, below the 50-day MA of 13.79, and below the 200-day MA of 15.33, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 74.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARDT.

Ardent Health Partners, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADUS	78 Outperform	$2.03B	24.93	9.18%	―	11.38%	10.29%
ASTH	73 Outperform	$1.25B	33.99	5.00%	―	54.81%	-45.07%
ARDT	72 Outperform	$1.92B	8.50	23.97%	―	8.91%	193.92%
SEM	64 Neutral	$1.94B	11.26	10.38%	1.65%	-8.86%	-36.22%
ACHC	60 Neutral	$2.14B	11.38	6.35%	―	5.48%	―
Sector *	46 Neutral	C$194.85M	-4.28	-8.56%	2.84%	13.52%	-1.74%
AGL	44 Neutral	$989.34M	―	-42.95%	―	19.18%	-6.14%

Ardent Health Partners, Inc. Corporate Events

Ardent Health Announces Departure of Hospital Operations President

On June 16, 2025, Ardent Health, Inc. announced the immediate departure of David Schultz from his role as President of Hospital Operations. His exit is classified as a ‘Qualifying Termination’ under the company’s Executive Severance Plan, entitling him to severance benefits as outlined in the company’s proxy statement and previous filings.

The most recent analyst rating on (ARDT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Ardent Health Partners, Inc. stock, see the ARDT Stock Forecast page.

Ardent Health Partners Announces Name Change to Ardent Health

On May 22, 2025, Ardent Health Partners, Inc. announced a name change to Ardent Health, Inc., effective June 3, 2025, with the amendment approved by the Board of Directors and not requiring stockholder approval. The company’s stock will continue trading under the symbol ‘ARDT’ on the New York Stock Exchange. At the Annual Meeting of Stockholders on May 21, 2025, 11 directors were elected, executive compensation was approved on a non-binding basis, and Ernst & Young LLP was ratified as the independent accounting firm for 2025.

The most recent analyst rating on (ARDT) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Ardent Health Partners, Inc. stock, see the ARDT Stock Forecast page.